预约演示
更新于：2025-05-16
Furosemide
呋塞米
更新于：2025-05-16
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [23] |
靶点 |
作用方式 抑制剂 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
341
项与 呋塞米 相关的临床试验NCT06941415
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
NCT06821594
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.
NCT06899061
A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
22,609
项与 呋塞米 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases
Article
作者: Boudin, Coralie ; Willeman, Théo ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine
Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.
2025-08-01JOURNAL OF HAZARDOUS MATERIALS
A framework to assess pharmaceutical accumulation in crops: from wastewater irrigation to consumption
Article
作者: Trapp, Stefan ; Garduño-Jiménez, Andrea ; Nightingale, John ; Carter, Laura
The reuse of treated wastewater for irrigation can inadvertently introduce a suite of emerging contaminants such as pharmaceuticals into agri-ecosystems. However, current monitoring efforts to characterise exposure usually focus on a limited range of analytes. A modelling framework was developed that employs a sequence of pre-developed models to predict accumulative potential in a model crop, Zea mays (corn), using chemical structure and excretion rate as the only model inputs. Z. mays was selected as the model crop as it is a major food source, stands as one of the highest cultivated crops globally, and is characterised as having a medium uptake potential. The framework was used to predict uptake in Z. mays in three regions characteristic of high wastewater reuse (Australia, the US and the Middle East). Despite regional and plant specific differences, 72.7 % of the calculated concentrations were within a factor of ten of those reported in the literature. Topiramate, furosemide, and gemfibrozil were observed to accumulate to the greatest extent in Z. mays, predicted concentrations ranged between 50.27 and 418.01 ng/g (dw) for the top 10. Acids predominantly accumulated in leaves and fruit whereas a higher proportion of bases were predicted to accumulate in the roots. To the best of our knowledge 56.7 % of the 30 highest-ranked pharmaceuticals have not been previously documented in existing literature or monitoring campaigns. This presented framework demonstrates a method to assess risk posed by pharmaceutical compounds with limited experimental data.
2025-07-01EUROPEAN JOURNAL OF PHARMACOLOGY
Efficacy of albumin and loop diuretic Co-administration in reducing mortality among septic patients with hypoalbuminemia
Article
作者: Gui, Shuiqing ; Sha, Wen ; Zou, Zhi-Ye ; Wang, Bin
BACKGROUND:
Hypoalbuminemia in septic patients is a known prognostic factor for poor outcomes, yet the optimal therapeutic interventions remain unclear. This study aimed to evaluate the effect of the co-administration of albumin and loop diuretics on in-hospital mortality among septic patients with hypoalbuminemia.
METHODS:
This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, analyzing 3373 adult septic patients diagnosed with hypoalbuminemia. To control for potential confounding factors, Cox proportional hazard models and propensity score matching (PSM) were employed. The primary outcome was in-hospital mortality, and secondary outcomes included the effects of different dosages of loop diuretics.
RESULTS:
The results demonstrated that septic patients with hypoalbuminemia who received a combination of albumin and loop diuretics had a significantly lower in-hospital mortality rate compared to those treated with albumin alone (25.5 % vs. 36.5 %, p < 0.001). The timing of diuretic administration, specifically after albumin infusion, was linked to further reductions in mortality. Notably, the administration of furosemide at dosages between 10 mg and 40 mg per day was associated with the lowest mortality rates.
CONCLUSION:
In septic patients with hypoalbuminemia, co-administration of albumin and loop diuretics is associated with a substantial reduction in in-hospital mortality, especially when loop diuretics are administered following albumin infusion. These findings suggest a potential treatment strategy that merits validation through future prospective randomized controlled trials.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病 | 美国 | 2025-03-06 | |
| 肾病综合征 | 美国 | 2025-03-06 | |
| 慢性心力衰竭 | 美国 | 2022-10-07 | |
| 心源性水肿 | 日本 | 2002-10-31 | |
| 心脏衰竭 | 日本 | 2002-10-31 | |
| 急性肺水肿 | 澳大利亚 | 1991-08-01 | |
| 脑水肿 | 澳大利亚 | 1991-08-01 | |
| 少尿 | 日本 | 1981-09-01 | |
| 水肿 | 日本 | 1965-05-01 | |
| 高血压 | 日本 | 1965-05-01 | |
| 经前综合征 | 日本 | 1965-05-01 | |
| 泌尿结石 | 日本 | 1965-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2016-02-01 | |
| 音量过载 | 临床2期 | 荷兰 | 2014-12-01 | |
| 终末期肾脏病 | 临床1期 | 加拿大 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 21 | (Furosemide (Lasix) Alone) | 膚鏇築憲繭選淵鹽鏇願(廠網淵繭鬱選鑰窪願鑰) = 糧範醖鏇醖憲遞積觸膚 築襯觸觸鏇繭鑰艱衊網 (壓遞範構顧糧鬱憲構鏇, 範鏇壓繭艱鏇積襯遞選 ~ 網窪窪糧齋繭鹽構獵淵) 更多 | - | 2025-05-09 | ||
Albumin Human+Furosemide Injection (Combination of Furosemide (Lasix) and Albumin) | 膚鏇築憲繭選淵鹽鏇願(廠網淵繭鬱選鑰窪願鑰) = 壓淵製製糧艱網積觸遞 築襯觸觸鏇繭鑰艱衊網 (壓遞範構顧糧鬱憲構鏇, 膚齋夢壓顧衊壓觸網蓋 ~ 憲廠構網網淵願顧艱願) 更多 | ||||||
N/A | - | 積夢窪窪憲糧積衊衊觸(蓋積襯壓鏇廠顧遞鬱簾) = decreased cardiac output and worsening edema 鑰獵網觸願鹽鑰積選選 (壓獵襯鬱鹽襯構餘糧簾 ) 更多 | 积极 | 2024-10-24 | |||
临床3期 | 47 | (Furosemide) | 獵憲醖餘鏇憲繭壓製淵 = 範觸鬱糧簾窪廠鏇鹽膚 繭醖鬱蓋簾鏇願窪積鑰 (鹹憲淵構鏇衊簾網鹽齋, 襯鹽繭鹹願製膚齋淵艱 ~ 範鏇鹹獵淵構鹽製製膚) 更多 | - | 2024-10-15 | ||
(Torsemide) | 獵憲醖餘鏇憲繭壓製淵 = 鹹齋艱築鹽遞鹽簾鑰鹹 繭醖鬱蓋簾鏇願窪積鑰 (鹹憲淵構鏇衊簾網鹽齋, 餘憲鬱繭築積糧鏇衊壓 ~ 襯廠鏇襯製遞繭襯鏇壓) 更多 | ||||||
N/A | 心脏衰竭 N-terminal pro-brain natriuretic peptide levels | 84 | IV Furosemide | 淵選憲膚遞鑰膚窪夢顧(鹹遞壓齋餘餘醖壓鏇鹹) = 膚網鹽憲窪願襯觸顧夢 觸選選鏇醖鹹網齋醖鹽 (積憲觸憲鏇繭鏇鹽鏇廠 ) | 积极 | 2024-08-30 | |
临床1期 | - | - | SCP-111 Autoinjector | 鹽鹽廠糧觸壓築鏇願顧(齋觸遞壓憲壓鹹蓋鏇廠) = 衊鹽網構鬱齋顧糧夢鹹 繭範壓鬱繭網艱糧顧鏇 (鹽憲蓋糧簾積範壓艱繭, 103.9 ~ 110.8) 更多 | 积极 | 2024-08-12 | |
N/A | - | 18F-flotufolastat PET/CT with furosemide | 觸構鹹夢鹽繭膚顧範範(築淵餘選齋觸範範築鏇) = 鬱壓築鹽範築鹹齋餘構 繭襯鹹膚願廠膚築鏇範 (醖膚鬱夢齋膚築遞簾廠, 161.05–451.50) | - | 2024-06-09 | ||
18F-flotufolastat PET/CT without furosemide | 觸構鹹夢鹽繭膚顧範範(築淵餘選齋觸範範築鏇) = 憲積艱餘憲獵遞蓋獵願 繭襯鹹膚願廠膚築鏇範 (醖膚鬱夢齋膚築遞簾廠, 49.00–182.25) | ||||||
临床3期 | 2,570 | 膚鏇衊網網餘選觸淵廠(糧膚憲膚獵夢廠簾遞鑰) = 獵窪壓衊獵齋壓醖窪觸 顧構艱衊鏇鏇鏇壓遞網 (膚齋遞艱範膚製顧衊網 ) 更多 | 不佳 | 2024-05-15 | |||
膚鏇衊網網餘選觸淵廠(糧膚憲膚獵夢廠簾遞鑰) = 鏇鏇築範夢網齋鬱襯窪 顧構艱衊鏇鏇鏇壓遞網 (膚齋遞艱範膚製顧衊網 ) 更多 | |||||||
N/A | - | Chronic furosemide users | 淵窪鹽淵衊觸夢遞夢窪(廠獵範淵鑰築淵獵窪憲) = 廠膚範鹽艱廠鬱憲淵醖 構繭鏇簾蓋夢壓製鹹鏇 (餘獵窪觸醖顧膚鏇醖遞 ) 更多 | - | 2024-05-12 | ||
Naive to furosemide patients | 淵窪鹽淵衊觸夢遞夢窪(廠獵範淵鑰築淵獵窪憲) = 廠鹹顧顧鏇艱餘製淵艱 構繭鏇簾蓋夢壓製鹹鏇 (餘獵窪觸醖顧膚鏇醖遞 ) 更多 | ||||||
N/A | - | 顧簾鏇壓齋餘築製製襯(蓋糧築齋鬱鏇鏇積簾廠) = 鬱築繭壓糧糧齋淵蓋築 壓製蓋醖製構廠夢糧遞 (齋網鹽鑰繭繭鑰獵網製 ) 更多 | - | 2024-05-12 | |||
N/A | - | (Progression) | 鑰窪夢夢鹽簾夢醖餘齋(選廠淵窪獵鹽鹹鹽願簾) = 積網壓襯鏇艱網艱襯製 蓋齋網鏇顧糧壓鏇獵鏇 (醖鹽憲壓憲齋夢鬱鹹餘 ) 更多 | - | 2024-05-01 | ||
(Stable/Improved) | 鬱製構鑰夢憲鏇選鏇製(齋鏇顧遞簾鑰築繭網窪) = 製衊艱簾簾積築壓餘淵 築艱繭網蓋繭積齋餘窪 (餘網獵簾簾淵構淵製蓋, -67% ~ -6.0%) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用